Dualogics has a growing pipeline of bispecific antibody therapies developed both internally and through collaborations. Bispecific antibodies have enabled exciting medical breakthroughs in the treatment of aggressive and hard to treat cancers, and we think these breakthroughs are just the beginning. Our pipeline of highly differentiated bispecific antibodies focuses on significant unmet medical needs in the areas of autoimmunity and immuno-oncology.
We are currently looking for strategic partners and investors to accelerate our various programs, please Contact Us to inquire about these opportunities. A representation of our current development pipeline is displayed below.
Dualogics was founded in 2015 and operates out of R&D space located in Chapel Hill, North Carolina. With access to state of the art computational and experimental equipment, we are well suited for the development and testing of bispecific antibody candidates.
Dualogics collaborates broadly to create bispecific antibodies from promising monoclonal antibodies. These collaborations range from single targets to library-wide projects and have functioned under a wide variety of collaboration and licensing structures.